Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | NNMT | P40261 | 4/20 | 0.38 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6712967 | 0.84 | CYP1A2 (0.49) | ALDH1A1CYP1A2POLBMTNR1AKDM4E | |
| SCHEMBL5717600 | 0.84 | KDM4E (0.47) | ALDH1A1CYP1A2POLBKDM4ELMNA | |
| SCHEMBL12479800 | 0.82 | CYP1A2 (0.47) | ALDH1A1CYP1A2HTTKDM4ELMNA | |
| SCHEMBL9874099 | 0.81 | KDM4E (0.47) | ALDH1A1CYP1A2POLBKDM4E | |
| SCHEMBL20520304 | 0.80 | MTNR1A (0.41) | ALDH1A1MTNR1AKDM4ENNMTSIRT6 | |
| SCHEMBL12479132 | 0.74 | KDM4E (0.43) | ALDH1A1CYP1A2HTTKDM4ESMN1; SMN2 | |
| SCHEMBL5092329 | 0.73 | CYP1A2 (0.48) | ALDH1A1CYP1A2POLBHTTKDM4E | |
| SCHEMBL13069321 | 0.72 | SMN1; SMN2 (0.42) | ALDH1A1CYP1A2KDM4ELMNASMN1; SMN2 | |
| SCHEMBL7013448 | 0.72 | ALDH1A1 (0.50) | ALDH1A1CYP1A2KDM4ELMNASMN1; SMN2 | |
| SCHEMBL1720666 | 0.72 | CYP1A2 (0.52) | ALDH1A1CYP1A2POLBHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363925-B8 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2007-04-25 | — | — | EP | disclosed |
| EP-1363925-B1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| US-20060211636-A1 | Macrolide Antibiotics | ALIHODZIC SULEJMAN | 2006-09-21 | — | — | US | disclosed |
| US-20050215495-A1 | Macrolide antibiotics | ALIHODZIC SULEJMAN | 2005-09-29 | — | — | US | disclosed |
| US-20040077557-A1 | Macrolide antibiotics | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | disclosed |
| EP-1363925-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002050091-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215495-A1 | Macrolide antibiotics | IL1R1, MRPL12, RPS21 | ALDH1A1 2549/4885CYP1A2 375/4885POLB 2625/4885 |
| US-20060211636-A1 | Macrolide Antibiotics | IL1R1, MRPL12, RPS21 | ALDH1A1 2549/4885CYP1A2 375/4885POLB 2625/4885 |
| US-20040077557-A1 | Macrolide antibiotics | MALT1, MRPL21, IL1R1 | ALDH1A1 2482/4885CYP1A2 362/4885POLB 2847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.